gliclazide has been researched along with Dyslipidemia in 5 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe one patient with diabetes mellitus treated by fenofibrate monotherapy since several years; 48 h after gliclazide therapy was introduced, rhabdomyolysis occurred." | 7.73 | [Rhabdomyolysis induced by fenofibrate monotherapy]. ( Amaniou, M; Archambeaud-Mouveroux, F; Combes, C; Galinat, S; Lassandre, S; Lopez, S; Teissier, MP, 2006) |
| "We describe one patient with diabetes mellitus treated by fenofibrate monotherapy since several years; 48 h after gliclazide therapy was introduced, rhabdomyolysis occurred." | 3.73 | [Rhabdomyolysis induced by fenofibrate monotherapy]. ( Amaniou, M; Archambeaud-Mouveroux, F; Combes, C; Galinat, S; Lassandre, S; Lopez, S; Teissier, MP, 2006) |
| "Gliclazide is a sulphonylurea antidiabetic drug with antioxidant effects due to its azabicyclo-octyl ring." | 1.35 | Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. ( Louro, T; Matafome, P; Monteiro, P; Nunes, E; Seiça, R; Sena, CM, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, KF | 1 |
| Mak, MWH | 1 |
| Lao, VWN | 1 |
| Yip, HLK | 1 |
| Lau, WY | 1 |
| Wong, VTL | 1 |
| Zhou, Y | 1 |
| Hu, C | 1 |
| Zhao, X | 1 |
| Luo, P | 1 |
| Lu, J | 1 |
| Li, Q | 1 |
| Chen, M | 1 |
| Yan, D | 1 |
| Lu, X | 1 |
| Kong, H | 1 |
| Jia, W | 1 |
| Xu, G | 1 |
| Betteridge, DJ | 1 |
| Vergès, B | 1 |
| Archambeaud-Mouveroux, F | 1 |
| Lopez, S | 1 |
| Combes, C | 1 |
| Lassandre, S | 1 |
| Amaniou, M | 1 |
| Teissier, MP | 1 |
| Galinat, S | 1 |
| Sena, CM | 1 |
| Louro, T | 1 |
| Matafome, P | 1 |
| Nunes, E | 1 |
| Monteiro, P | 1 |
| Seiça, R | 1 |
1 trial available for gliclazide and Dyslipidemia
| Article | Year |
|---|---|
Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2005 |
4 other studies available for gliclazide and Dyslipidemia
| Article | Year |
|---|---|
Immune-mediated necrotising myopathy is a rare statin-associated adverse effect: a case report.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Gliclazid | 2020 |
Serum Metabolomics Study of Gliclazide-Modified-Release-Treated Type 2 Diabetes Mellitus Patients Using a Gas Chromatography-Mass Spectrometry Method.
Topics: Adult; Biomarkers; Diabetes Mellitus, Type 2; Dyslipidemias; Eicosapentaenoic Acid; Female; Gas Chro | 2018 |
[Rhabdomyolysis induced by fenofibrate monotherapy].
Topics: Diabetes Mellitus; Drug Interactions; Dyslipidemias; Fenofibrate; Follow-Up Studies; Gliclazide; Hum | 2006 |
Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylcholine; Animals; Antioxidants; Body Weight; Deoxyguanosine; Diab | 2009 |